Please assess the completion status of the following clinical trial:

Trial Title: A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with Type 2 Diabetes for at least three months prior to study~* Diabetes treated with metformin only~* Give consent and sign an informed consent form.~* Agree to follow specific requirements of birth control during participation.~Exclusion Criteria:~* Type I Diabetes.~* Treatment with insulin within 3 months prior to screening~* History of diabetic ketoacidosis or lactic acidosis~* Allergy or sensitivity to metformin or similar drugs or any medical conditions which prohibit metformin use~* Excessive blood donation 56 days before the start of the study~* Urinary tract or bladder infections within four weeks of study start~* Alcohol abuse or illicit drug use within 12 months of study start~* Receiving other investigational drugs or participating in other research trials within 30 of the study start~* Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements with 7-14 days of study start~* Live alone without regular, daily interactions with someone who can be an emergency contact

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Subjects receiving treatment P (Type: PLACEBO_COMPARATOR): Eligible subjects will receive placebo twice daily along with metformin twice daily for 13 days.
- Subjects receiving treatment A (Type: EXPERIMENTAL): Eligible subjects will receive GSK189075 500 milligrams twice daily along with metformin twice daily for 13 days.
- Subjects receiving treatment B (Type: EXPERIMENTAL): Eligible subjects will receive GSK189075 750 milligrams twice daily along with metformin twice daily for 13 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).